TY - JOUR
T1 - Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function
T2 - The HORMA trial
AU - Sattler, Fred
AU - Bhasin, Shalender
AU - He, Jiaxiu
AU - Chou, Chih Ping
AU - Castaneda-Sceppa, Carmen
AU - Yarasheski, Kevin
AU - Binder, Ellen
AU - Schroeder, E. Todd
AU - Kawakubo, Miwa
AU - Zhang, Anqi
AU - Roubenoff, Ronenn
AU - Azen, Stanley
N1 - Funding Information:
Support for this trial was provided by the National Institute of Aging (AG18169) and NCRR M0I RR000043 at USC and RR000036 at Washington University, grants AG22356 and AG031679 at Boston Medical Center, and USDA grant (58-1950-9-001) and NCRR RR000054 at Tufts University. Study therapies were provided by Solvay Pharmaceuticals Inc., Genentech Inc., and Tap Pharmaceutical Products Inc.
PY - 2011/1
Y1 - 2011/1
N2 - Background: In the HORMA (Hormonal Regulators of Muscle and Metabolism in Aging) Trial, supplemental testosterone and recombinant human growth hormone (rhGH) enhanced lean body mass, appendicular skeletal muscle mass, muscle performance, and physical function, but there was substantial interindividual variability in outcomes. Methods: One hundred and twelve men aged 65-90 years received testosterone gel (5 g/d vs 10 g/d via Leydig cell clamp) and rhGH (0 vs 3 vs 5 μg/kg/d) in a double-masked 2 × 3 factorial design for 16 weeks. Outcomes included lean tissue mass by dual energy x-ray absorptiometry, one-repetition maximum strength, Margaria stair power, and activity questionnaires. We used pathway analysis to determine the relationship between changes in hormone levels, muscle mass, strength, and function. Results: Increases in total testosterone of 1046 ng/dL (95% confdence interval = 1040-1051) and 898 ng/dL (95% confdence interval = 892-904) were necessary to achieve median increases in lean body mass of 1.5 kg and appendicular skeletal muscle mass of 0.8 kg, respectively, which were required to significantly enhance one-repetition maximum strength (≥30%). Co-treatment with rhGH lowered the testosterone levels (quantified using liquid chromatographytandem mass spectrometry) necessary to reach these lean mass thresholds. Changes in one-repetition maximum strength were associated with increases in stair climbing power (r =.26, p =.01). Pathway analysis supported the model that changes in testosterone and insulin-like growth factor 1 levels are related to changes in lean body mass needed to enhance muscle performance and physical function. Testosterone's effects on physical activity were mediated through a different pathway because testosterone directly affected Physical Activity Score of the Elderly. Conclusions: To enhance muscle strength and physical function, threshold improvements in lean body mass and appendicular skeletal muscle mass are necessary and these can be achieved by targeting changes in testosterone levels. rhGH augments the effects of testosterone. To maximize functional improvements, the doses of anabolic hormones should be titrated to achieve target blood levels.
AB - Background: In the HORMA (Hormonal Regulators of Muscle and Metabolism in Aging) Trial, supplemental testosterone and recombinant human growth hormone (rhGH) enhanced lean body mass, appendicular skeletal muscle mass, muscle performance, and physical function, but there was substantial interindividual variability in outcomes. Methods: One hundred and twelve men aged 65-90 years received testosterone gel (5 g/d vs 10 g/d via Leydig cell clamp) and rhGH (0 vs 3 vs 5 μg/kg/d) in a double-masked 2 × 3 factorial design for 16 weeks. Outcomes included lean tissue mass by dual energy x-ray absorptiometry, one-repetition maximum strength, Margaria stair power, and activity questionnaires. We used pathway analysis to determine the relationship between changes in hormone levels, muscle mass, strength, and function. Results: Increases in total testosterone of 1046 ng/dL (95% confdence interval = 1040-1051) and 898 ng/dL (95% confdence interval = 892-904) were necessary to achieve median increases in lean body mass of 1.5 kg and appendicular skeletal muscle mass of 0.8 kg, respectively, which were required to significantly enhance one-repetition maximum strength (≥30%). Co-treatment with rhGH lowered the testosterone levels (quantified using liquid chromatographytandem mass spectrometry) necessary to reach these lean mass thresholds. Changes in one-repetition maximum strength were associated with increases in stair climbing power (r =.26, p =.01). Pathway analysis supported the model that changes in testosterone and insulin-like growth factor 1 levels are related to changes in lean body mass needed to enhance muscle performance and physical function. Testosterone's effects on physical activity were mediated through a different pathway because testosterone directly affected Physical Activity Score of the Elderly. Conclusions: To enhance muscle strength and physical function, threshold improvements in lean body mass and appendicular skeletal muscle mass are necessary and these can be achieved by targeting changes in testosterone levels. rhGH augments the effects of testosterone. To maximize functional improvements, the doses of anabolic hormones should be titrated to achieve target blood levels.
KW - Growth hormone
KW - Lean body mass
KW - Muscle performance
KW - Physical function
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=79951591595&partnerID=8YFLogxK
U2 - 10.1093/gerona/glq183
DO - 10.1093/gerona/glq183
M3 - Article
C2 - 21059836
AN - SCOPUS:79951591595
SN - 1079-5006
VL - 66 A
SP - 122
EP - 129
JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
IS - 1
ER -